Olr1488 inhibitors are a specialized class of chemical compounds designed to specifically target and inhibit the Olr1488 receptor, which is part of the olfactory receptor family within the G-protein coupled receptor (GPCR) superfamily. Olfactory receptors, including Olr1488, are primarily involved in detecting and responding to specific odorant molecules, playing a crucial role in the process of olfactory signal transduction. These receptors function by binding to particular ligands, which initiates a cascade of intracellular signaling events that ultimately result in the transmission of sensory information. Inhibitors of Olr1488 are developed to interfere with this process by binding to the receptor, thereby preventing its natural ligands from activating it. This inhibition can occur through direct competition with the ligands at the receptor's active site or by binding to allosteric sites, which may cause conformational changes that reduce the receptor's ability to function.
The development of Olr1488 inhibitors involves a detailed and systematic approach to optimizing their chemical properties, such as binding affinity, selectivity, and stability. Researchers utilize molecular modeling and docking simulations to predict how these inhibitors interact with the Olr1488 receptor, providing valuable insights into potential binding sites and the structural requirements for effective inhibition. High-throughput screening techniques are also employed to identify lead compounds from large chemical libraries, followed by structure-activity relationship (SAR) studies that refine the chemical structure of these inhibitors to enhance their inhibitory potency and specificity. Key considerations in the design of Olr1488 inhibitors include their ability to selectively bind to the Olr1488 receptor without affecting other similar receptors, as well as their physicochemical properties like solubility, lipophilicity, and metabolic stability, which are essential for ensuring that these inhibitors can function effectively in various biological environments. The study and refinement of Olr1488 inhibitors provide important insights into the molecular mechanisms of olfactory receptor function and the broader field of GPCR-mediated signal transduction.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Beta-adrenergic antagonist, could modulate GPCR activity, potentially affecting Olr1488. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Beta-adrenergic antagonist with alpha-1 blocking, might influence Olr1488 signaling pathways. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Alpha-2 adrenergic receptor antagonist, could affect GPCR signaling pathways related to Olr1488. | ||||||
Labetalol | 36894-69-6 | sc-484723 | 50 mg | $180.00 | ||
Combined alpha and beta blocker, might indirectly affect GPCR pathways including Olr1488. | ||||||
Pindolol | 13523-86-9 | sc-204847 sc-204847A | 100 mg 1 g | $194.00 $760.00 | ||
Beta-adrenergic antagonist, may influence GPCR-mediated signaling pathways related to Olr1488. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Beta-adrenergic agonist, might indirectly affect Olr1488 through GPCR modulation. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $204.00 | 2 | |
Muscarinic acetylcholine receptor antagonist, may influence GPCR signaling pathways including Olr1488. | ||||||
Salmeterol | 89365-50-4 | sc-224277 sc-224277A | 10 mg 50 mg | $186.00 $562.00 | 1 | |
Beta-2 adrenergic agonist, potentially affecting GPCR pathways related to Olr1488. | ||||||
Alprenolol | 13655-52-2 | sc-507469 | 50 mg | $130.00 | ||
Beta blocker, could indirectly influence GPCR signaling pathways including Olr1488. | ||||||